MACC1 INVOLVED IN THE REGULATION OF RESISTANCE OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE GASTRIC CANCER CELLS TO TRASTUZUMAB

被引:0
|
作者
Zhang, Guofei [1 ]
Hu, Kefu [1 ]
Yu, Rong [1 ]
Su, Gang [1 ]
Xiong, Xin [1 ]
Hu, Daqian [1 ]
Zhang, Zhihong [1 ]
机构
[1] Gongan Cty Peoples Hosp, Dept Oncol, Shizikou Town, Gongan County, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2019年 / 35卷 / 05期
关键词
MACC1; gene; human HER2-positive gastric cells; trastuzumab; resistance; POOR-PROGNOSIS; EXPRESSION; LONG;
D O I
10.19193/0393-6384_2019_5_381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We sought to analyze whether the mechanism of the MACC1 gene involved in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells regulates trastuzumab-resistant gastric cancer. Methods: Cell lines sensitive to trastuzumab and positive for MACC1 and HER2 expression were screened from human gastric cancer cell lines, drug-resistant cell MKN45/TR was established by a stepwise dose-increase method, and the expression level o f MACC1 protein in trastuzumab-resistant cells was detected using Western blot. The inhibition rate of cell proliferation after trastuzumab treatment for 72 hours was detected using MTT. Results: Drug-resistant cell MKN45/TR was established using a stepwise dose-increase method. Half-maximal inhibitory concentration and resistance index of cell trastuzumab were detected during the induction period .The induction time was five months and the final induction concentration was 2,500 mu g/mL. Additionally, the half-maximal inhibitory concentration of trastuzumab was 295.15 mu g/mL and the drug resistance index was 9.67. Western blot detection results showed that, as compared with cells without drug resistance, the MACC1 protein level of trastuzumab-resistant cells obviously increased. NCI-N87/TR and MKN45/TR were given transinfection using MACC1 interference and empty vector and were treated using different concentrations of trastuzumab. The cell inhibition rate was detected using the MTT method. Under the function of trastuzumab at concentrations of 20 mu g/mL, 80 mu g/mL, and 160 mu g/mL, there was statistical significance between the interference group and the control group with respect to the inhibition rate of cell proliferation (P<0.05). Conclusion: MACC1 participates in the regulation of trastuzumab in gastric cancer cells. The expression level of MACC1 protein cells in transinfection resistance increases, thus interfering MACC1 in resistance cells and reversing the resistance of MACC1.
引用
收藏
页码:2439 / 2443
页数:5
相关论文
共 50 条
  • [31] Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery
    Cheun, Jong Ho
    Won, Jiyoung
    Jung, Ji Gwang
    Kim, Hong Kyu
    Han, Wonshik
    Lee, Han Byoel
    JOURNAL OF BREAST CANCER, 2021, 24 (03) : 301 - 314
  • [32] The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
    Kim, Hye Ryeon
    Ahn, Soomin
    Jo, Hyunji
    Kim, Hongsik
    Hong, Joohyun
    Lee, Jeeyun
    Lim, Ho-Yeong
    Kang, Won Ki
    Kim, Seung Tae
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
    Zoe Kemp
    Alison Jones
    Advances in Therapy, 2011, 28 : 603 - 614
  • [34] Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (06) : 1268 - 1274
  • [35] Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer
    Suzuki, Yasuhiro
    Ogiya, Rin
    Oshitanai, Risa
    Terao, Mayako
    Terada, Mizuho
    Morioka, Toru
    Tsuda, Banri
    Niikura, Naoki
    Okamura, Takuho
    Saito, Yuki
    Tokuda, Yutaka
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (02) : 274 - 279
  • [36] Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer
    Zardavas, Dimitrios
    Bozovic-Spasojevic, Ivana
    De Azambuja, Evandro
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (06) : 612 - 622
  • [37] Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome
    Krell, Jonathan
    James, Colin R.
    Shah, Deep
    Gojis, Ondrej
    Lim, Adrian
    Riddle, Pippa
    Ahmad, Riz
    Makris, Andreas
    Cowdray, Andrew
    Chow, Angela
    Babayev, Tamerlan
    Madden, Peter
    Leonard, Robert
    Cleator, Susan
    Palmieri, Carlo
    CLINICAL BREAST CANCER, 2011, 11 (03) : 153 - 160
  • [38] New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023
    Banys-Paluchowski, Maggie
    Krawczyk, Natalia
    Stickeler, Elmar
    Mueller, Volkmar
    Fehm, Tanja
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2023, 35 (01) : 54 - 61
  • [39] Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
    Larionov, Alexey A.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [40] Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer
    Chung, Clement
    Lam, Masha S. H.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (18) : 1579 - 1587